Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Abstracts

Abstracts need predictive biomarkers for patients with wildtype tumors. We must KEYNOTE LECTURES recognize that EGFR TKI such as erlotinib can improve DFS and OS even in EGFR wt tumors. 1IN There has been limited study of EGFR TKIs in patients with Stage I-III TOBACCO CONTROL-WHAT IS IMPORTANT FOR NSCLC. These agents have the potential to improve the cure rate in the early ONCOLOGISTS TO KNOW stage patients. Oncogenes can be activated by fusion with other genes as well as by mutation in NSCLC. The EML4/ALK fusion gene is present in about C. Dresler Tobacco Prevention and Cessation Program, Arkansas Depart- 4% of lung adenocarcinomas essentially limited to never smokers. Patients ment of Health, Little Rock/USA whose tumors harbor these fused genes have high ALK expression and had The known relationship between tobacco and lung cancer goes back to the high response rates to the ALK TKI term PF1066 in a phase I trial of this 1950s. Despite this knowledge, lung cancer remains the leading cause of agent. These results have led to a phase II/III randomized trial in these cancer deaths in developed countries, and is becoming so in developing patients. Many of these oncogenic transformations lead to activation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/abstracts-1bE6MDqjfV
ISSN
1556-0864
eISSN
1556-1380

Abstract

need predictive biomarkers for patients with wildtype tumors. We must KEYNOTE LECTURES recognize that EGFR TKI such as erlotinib can improve DFS and OS even in EGFR wt tumors. 1IN There has been limited study of EGFR TKIs in patients with Stage I-III TOBACCO CONTROL-WHAT IS IMPORTANT FOR NSCLC. These agents have the potential to improve the cure rate in the early ONCOLOGISTS TO KNOW stage patients. Oncogenes can be activated by fusion with other genes as well as by mutation in NSCLC. The EML4/ALK fusion gene is present in about C. Dresler Tobacco Prevention and Cessation Program, Arkansas Depart- 4% of lung adenocarcinomas essentially limited to never smokers. Patients ment of Health, Little Rock/USA whose tumors harbor these fused genes have high ALK expression and had The known relationship between tobacco and lung cancer goes back to the high response rates to the ALK TKI term PF1066 in a phase I trial of this 1950s. Despite this knowledge, lung cancer remains the leading cause of agent. These results have led to a phase II/III randomized trial in these cancer deaths in developed countries, and is becoming so in developing patients. Many of these oncogenic transformations lead to activation

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: May 1, 2010

There are no references for this article.